Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 9, 2015, Pages 2847-2852

  McLean, Kirsty J ^a   Hans, Marcus ^b   Meijrink, Ben ^b   Van Scheppingen, Wibo B ^b   Vollebregt, Aad ^b   Tee, Kang Lan ^a   Van Der Laan, Jan Metske ^b   Leys, David ^a   Munro, Andrew W ^a   Van Den Berg, Marco A ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b DSM BIOTECHNOLOGY CENTER   (Netherlands)

Author keywords

Cholesterol; Fermentation; P450 engineering; Pravastatin; Statin

Indexed keywords

ANTIBIOTIC AGENT; CHOLESTEROL; COMPACTIN; COMPACTIN HYDROXYLASE; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 105AS1; OXYGENASE; PRAVASTATIN; UNCLASSIFIED DRUG; FUNGAL PROTEIN;

AMYCOLATOPSIS ORIENTALIS; ANIMAL CELL; ARTICLE; BACTERIA; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG HYDROXYLATION; DRUG MANUFACTURE; DRUG PROTEIN BINDING; ENZYME SUBSTRATE; EPIMER; EPIMERIZATION; FERMENTATION; FRACTIONATION; GENE EXPRESSION; GENE MUTATION; NONHUMAN; OXIDATION; PENICILLIUM CHRYSOGENUM; PRIORITY JOURNAL; STEREOCHEMISTRY; WILD TYPE; BIOSYNTHESIS; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; STEREOISOMERISM; X RAY CRYSTALLOGRAPHY;

AMYCOLATOPSIS ORIENTALIS; PENICILLIUM CHRYSOGENUM;

BASE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; FUNGAL PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; PENICILLIUM CHRYSOGENUM; PRAVASTATIN; STEREOISOMERISM;

EID: 84924189921     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1419028112     Document Type: Article

References (49)

1. Weng TC, Yang YHK, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35(2): 139-151.
2. Lamon-Fava S (2013) Statins and lipid metabolism: An update. Curr Opin Lipidol 24(3): 221-226.
3. Roth BD (2002) The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Progress in Medicinal Chemistry, eds King FD, Oxford AW (Elsevier Science BV, Amsterdam), Vol 40, pp 1-22.
4. Yoshino G, et al. (1986) Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. Diabetes Res Clin Pract 2(3): 179-181.
5. Serizawa N (1996) Biochemical and molecular approaches for production of pravastatin, a potent cholesterol-lowering drug. Biotechnol Annu Rev 2: 373-389.
6. Kennedy J, et al. (1999) Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. Science 284(5418): 1368-1372.
7. Abe Y, et al. (2002) Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum. Mol Genet Genomics 267(5): 636-646.
8. Thaper RK, Kumar Y, Kumar SMD, Misra S, Khanna JM (1999) A cost-efficient synthesis of simvastatin via high-conversion methylation of an alkoxide ester enolate. Org Process Res Dev 3(6): 476-479.
9. Matsuoka T, et al. (1989) Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem 184(3): 707-713.
10. Guengerich FP (2005) Human cytochrome P450 enzymes. Cytochrome P450: Structure, Mechanism and Biochemstry, 3rd Ed, ed Ortiz de Montellano PR (Kluwer Academic/Plenum Publishers, New York), pp 377-530.
11. Podust LM, Sherman DH (2012) Diversity of P450 enzymes in the biosynthesis of natural products. Nat Prod Rep 29(10): 1251-1266.
12. Neuvonen PJ (2010) Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11(3): 323-332.
13. Hosobuchi M, Kurosawa K, Yoshikawa H (1993) Application of computer to monitoring and control of fermentation process: Microbial conversion of ML-236B Na to pravastatin. Biotechnol Bioeng 42(7): 815-820.
14. van den Berg MA (2011) Impact of the Penicillium chrysogenum genome on industrial production of metabolites. Appl Microbiol Biotechnol 92(1): 45-53.
15. Harris DM, et al. (2009) Exploring and dissecting genome-wide gene expression responses of Penicillium chrysogenum to phenylacetic acid consumption and penicillinG production. BMC Genomics 10: 75.
16. van den Berg MA, et al. (2008) Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum. Nat Biotechnol 26(10): 1161-1168.
17. Chen C-H, Hu H-Y, Cho Y-C, Hsu W-H (2006) Screening of compactin-resistant microorganisms capable of converting compactin to pravastatin. Curr Microbiol 53(2): 108-112.
18. Fujii Y, et al. (2011) Construction of a novel expression vector in Pseudonocardia autotrophica and its application to efficient biotransformation of compactin to pravastatin, a specific HMG-CoA reductase inhibitor. Biochem Biophys Res Commun 404(1): 511-516.
19. Lin C-L, Tang Y-L, Lin S-M (2011) Efficient bioconversion of compactin to pravastatin by the quinoline-degrading microorganism Pseudonocardia carboxydivorans isolated from petroleum-contaminated soil. Bioresour Technol 102(22): 10187-10193.
20. Park JW, et al. (2003) Bioconversion of compactin into pravastatin by Streptomyces sp. Biotechnol Lett 25(21): 1827-1831.
21. Peng Y, Yashphe J, Demain AL (1997) Biotransformation of compactin to pravastatin by Actinomadura sp. 2966. J Antibiot (Tokyo) 50(12): 1032-1035.
22. Serizawa N, et al. (1983) Microbial hydroxylation of ML-236B (compactin). Studies on microorganisms capable of 3 beta-hydroxylation of ML-236B. J Antibiot (Tokyo) 36(7): 887-891.
23. Nodate M, Kubota M, Misawa N (2006) Functional expression system for cytochrome P450 genes using the reductase domain of self-sufficient P450RhF from Rhodococcus sp. NCIMB 9784. Appl Microbiol Biotechnol 71(4): 455-462.
24. Fuziwara S, et al. (2002) Catalytically functional flavocytochrome chimeras of P450 BM3 and nitric oxide synthase. J Inorg Biochem 91(4): 515-526.
25. Sieber V, Martinez CA, Arnold FH (2001) Libraries of hybrid proteins from distantly related sequences. Nat Biotechnol 19(5): 456-460.
26. Sugimoto H, et al. (2008) Crystal structure of CYP105A1 (P450SU-1) in complex with 1alpha,25-dihydroxyvitamin D3. Biochemistry 47(13): 4017-4027.
27. Xu L-H, et al. (2010) Regio- and stereospecificity of filipin hydroxylation sites revealed by crystal structures of cytochrome P450 105P1 and 105D6 from Streptomyces avermitilis. J Biol Chem 285(22): 16844-16853.
28. Butler CF, et al. (2013) Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias. J Biol Chem 288(35): 25387-25399.
29. Smith RG (2008) Penicillin and cephalosporin drug allergies: A paradigm shift. J Am Podiatr Med Assoc 98(6): 479-488.
30. Jami MS, et al. (2010) The Penicillium chrysogenum extracellular proteome. Conversion from a food-rotting strain to a versatile cell factory for white biotechnology. Mol Cell Proteomics 9(12): 2729-2744.
31. Serizawa N, et al. (1983) 6 alpha-Hydroxy-iso-ML-236B (6 alpha-hydroxy-iso-compactin) and ML-236A, microbial transformation products of ML-236B. J Antibiot (Tokyo) 36(7): 918-920.
32. Komagata D, Yamashita H, Endo A (1986) Microbial conversion of compactin (ML-236B) to ML-236A. J Antibiot (Tokyo) 39(11): 1574-1577.
33. Galgóczy L, Nyilasi I, Papp T, Vágvölgyi C (2011) Statins as antifungal agents. World J Clin Infect Dis 1(1): 4-10.
34. Abe Y, et al. (2002) Effect of increased dosage of the ML-236B (compactin) biosynthetic gene cluster on ML-236B production in Penicillium citrinum. Mol Genet Genomics 268(1): 130-137.
35. Dodhia VR, Fantuzzi A, Gilardi G (2006) Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. J Biol Inorg Chem 11(7): 903-916.
36. Li P, Guan H, Li J, Lin Z (2009) Heterologous expression, purification, and characterization of cytochrome P450sca-2 and mutants with improved solubility in Escherichia coli. Protein Expr Purif 65(2): 196-203.
37. Fujii T, Fujii Y, Machida K, Ochiai A, Ito M (2009) Efficient biotransformations using Escherichia coli with tolC acrAB mutations expressing cytochrome P450 genes. Biosci Biotechnol Biochem 73(4): 805-810.
38. Ba L, Li P, Zhang H, Duan Y, Lin Z (2013) Semi-rational engineering of cytochrome P450sca-2 in a hybrid system for enhanced catalytic activity: Insights into the important role of electron transfer. Biotechnol Bioeng 110(11): 2815-2825.
39. Ba L, Li P, Zhang H, Duan Y, Lin Z (2013) Engineering of a hybrid biotransformation system for cytochrome P450sca-2 in Escherichia coli. Biotechnol J 8(7): 785-793.
40. Basch J, Chiang S-J (2007) Cloning and expression of a cytochrome P450 hydroxylase gene from Amycolatopsis orientalis: Hydroxylation of epothilone B for the production of epothilone F. J Ind Microbiol Biotechnol 34(2): 171-176.
41. Jung ST, Lauchli R, Arnold FH (2011) Cytochrome P450: Taming a wild type enzyme. Curr Opin Biotechnol 22(6): 809-817.
42. Trefzer A, et al. (2007) Biocatalytic conversion of avermectin to 4''-oxo-avermectin: Improvement of cytochrome p450 monooxygenase specificity by directed evolution. Appl Environ Microbiol 73(13): 4317-4325.
43. Manzoni M, Rollini M (2002) Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 58(5): 555-564.
44. Elander RP (2002) University of Wisconsin contributions to the early development of penicillin and cephalosporin antibiotics. SIM News 52: 270-278.
45. Benedetti A, Manzoni M, Nichele M, Rollini M (2002) Process for the production of pravastatin and lovastatin. Patent EP1266967.
46. D'Arcy A, Villard F, Marsh M (2007) An automated microseed matrix-screening method for protein crystallization. Acta Crystallogr D Biol Crystallogr 63(Pt 4): 550-554.
47. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66(Pt 2): 125-132.
48. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67(Pt 4): 235-242.
49. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1): 2126-2132.